Product Images Pregabalin

The text appears to be a chart showing the percentage of patients improved and the percentage improvement in pain from the baseline. It is not clear what the numbers correspond to or what the context is.*

This is a table with information regarding the percentage of patients improved after taking Pregabalin 160mg for three days. It also includes some numbers that may indicate the improvement in pain from baseline, but it is not clear how they relate to the previous information. Some characters are not recognizable, so the text is not fully understandable.*

The text appears to be a table that describes the dosage and improvement in pain for three different medications: Fregabalin, Pregataiin, and Placebo. The table shows the number of patients who improved after taking each medication, and the percentage improvement in pain from the baseline. However, there are some characters that are not readable, which may affect the accuracy of the information provided.*

This appears to be a table or chart that shows the dosages (ranging from placebo to 600mg/day) and results of multiple studies (E1, E3, S5) for an undisclosed medication or treatment. The mention of "statistically significant vs. placebo" suggests that the medication/treatment had a positive impact on the study participants, compared to those who received a placebo. However, without more context it is not possible to provide additional information on the study or its findings.*

The text contains a graph showing percent improvement in pain from baseline for patients taking different doses of Pregabalin and placebo. The x-axis shows the range of improvement percentage and the y-axis shows the number of patients. The graph suggests that Pregabalin at a daily dose of 300mg and 450mg can lead to higher improvement in pain compared to placebo.*

This appears to be a chart showing estimated percentages of subjects without LTR (likely an abbreviation for some medical condition) over a period of 120 days. The chart also includes two groups (Progabain and Placebo) which may have received different treatments. However, there is not enough information to fully understand the context or purpose of the chart.*

The text is presenting a chart that shows the percentage of subjects who improved during the course of a study. The chart displays two groups - one who received Pregabalin and one who received Placebo. The X-axis shows the measurement points at different weeks, while the Y-axis displays the percentage of subjects who improved. The percent of subjects improved at week 16 from baseline is displayed from 210 to 270. However, there seem to be some formatting issues, as parts of the chart are not displaying properly.*

This text appears to be a calculation formula for CLCT (creatinine clearance) which requires the patient's age, weight, and serum creatinine level. The formula instructs to subtract the patient's age in years from 140, then multiply the result by the patient's weight in kilograms. For female patients, the result should be multiplied by 0.85, and then further multiplied by their serum creatinine level in milligrams per deciliter (mg/dL). The final value obtained from this calculation would give the estimation of the patient's creatinine clearance (CLCT).*